immune system
• splenocytes show enhanced cell proliferation after lipopolysaccharide (LPS) or CpG treatments
|
• mutants show enhanced chemokine induction in the lung and colon, but not the liver, after IL-1 injection and for a longer time than in wild-type mice
|
• mice show a more potent inflammatory response than wild-type controls when injected with TLR4 activator LPS
• primary kidney cells and splenocytes show enhanced activation in response to either IL-1 or Toll ligands
|
• mutants exhibit reduced survival after endotoxin (LPS) challenge, with only a 10% survival compared to 70% in wild-type mice
|
hematopoietic system
• splenocytes show enhanced cell proliferation after lipopolysaccharide (LPS) or CpG treatments
|
cellular
• splenocytes show enhanced cell proliferation after lipopolysaccharide (LPS) or CpG treatments
|